SCHEMBL10145276

SCHEMBL10145276

O=C(O)c1cnc(N2CCCc3ccccc32)nc1C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
HPGD P15428 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
MAPT P10636 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
TP53 P04637 2/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
HCRTR1 O43613 1/20 0.43
HCRTR2 O43614 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
LMNA P02545 2/20 0.42
ALOX15 P16050 1/20 0.42
MAPK1 P28482 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12796000 0.87 ALDH1A1 (0.54) ALDH1A1NPC1RAB9AHPGDRXFP1
SCHEMBL12796228 0.85 NR1H2 (0.43) ALDH1A1NPC1RAB9AHPGDRXFP1
SCHEMBL10146157 0.82 NR1H2 (0.42) ALDH1A1NPC1RAB9AHPGDRXFP1
SCHEMBL12796050 0.81 ALDH1A1 (0.46) ALDH1A1NPC1RAB9AHPGDRXFP1
SCHEMBL12796052 0.79 ALDH1A1 (0.46) ALDH1A1NPC1RAB9AHPGDRXFP1
SCHEMBL12796505 0.78 TSHR (0.48) ALDH1A1NPC1RAB9AHPGDRXFP1
SCHEMBL12796019 0.78 RXRA (0.43) ALDH1A1NFKB1NFKB2RELAHCRTR1
SCHEMBL12796048 0.77 PTPN11 (0.57) ALDH1A1NPC1RAB9AHPGDMAPT
SCHEMBL10145798 0.74 KMT2A (0.45) ALDH1A1NPC1RAB9AHPGDRXFP1
SCHEMBL2396006 0.74 KCNJ2 (0.41) ALDH1A1RAB9AMAPTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130310373-A1 PYRIMIDINE COMPOUND ASTELLAS PHARMA INC. (JP) 2013-11-21 US disclosed
US-8524727-B2 Pyrimidine compound ASTELLAS PHARMA INC. (JP) 2013-09-03 US disclosed
US-8524727-B2 Pyrimidine compound ASTELLAS PHARMA INC. (JP) 2013-09-03 US disclosed
EP-2415765-A1 PYRIMIDINE COMPOUND Astellas Pharma Inc. (JP) 2012-02-08 EP disclosed
US-20110053912-A1 PYRIMIDINE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-03-03 US disclosed
US-20110053912-A1 PYRIMIDINE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-03-03 US disclosed
WO-2010113834-A1 PYRIMIDINE COMPOUND アステラス製薬株式会社 (JP) 2010-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053912-A1 PYRIMIDINE COMPOUND CNR2, CNR1, P2RY2 ALDH1A1 3897/4885NPC1 2248/4885RAB9A 2804/4885
US-20130310373-A1 PYRIMIDINE COMPOUND CNR2, CNR1, P2RY2 ALDH1A1 4050/4885NPC1 2300/4885RAB9A 2695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.